4AIM Sicaf S.p.A. (AIM)
XMIL 
Summary
AIM Chart
Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers pace
Ionic Rare Earths Ltd (ASX:IXR, OTC:IXRRF) is advancing plans to list its shares on London's AIM market in the fourth quarter of 2026 as it builds its UK presence and progresses commercialisation of its rare earth magnet recycling technology. The proposed AIM admission would complement IonicRE's existing ASX listing and is expected to broaden the company's access to UK and European investors with an interest in critical minerals and the energy transition.
Ondine Biomedical pauses trading to raise fresh investment after positive phase III result
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the developer of light-activated nasal disinfection for hospital patients, has suspended trading in its shares while it raises new investment to capitalise on its clinical and commercial progress. The company is one of a growing band of growth companies to use AIM's new Capital Access Window, a voluntary pause in share trading designed to widen the pool of investors and keep the price stable during a fundraise.
1947 Oil & Gas starts AIM trading after £50m fundraising and Gulf acquisition
1947 Oil & Gas, a newly listed oil and gas producer focused on US assets, began trading on London's AIM market on Monday with an initial valuation of about £65 million. The company issued 500 million shares at 10p each, raising £50 million through a combination of shares issued to the vendor of Renaissance Offshore and a placing with new investors.
4AIM Sicaf S.p.A. (AIM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 4AIM Sicaf S.p.A. ever had a stock split?
4AIM Sicaf S.p.A. Profile
| Biotechnology Industry | Healthcare Sector | Thomas K. Equels CEO | XMIL Exchange | US00901B3033 ISIN |
| US Country | 19 Employees | - Last Dividend | 10 Feb 2026 Last Split | 12 Jul 1996 IPO Date |
Overview
AIM ImmunoTech Inc. is an immuno-pharma company primarily engaged in the research and development of therapeutic treatments for a wide variety of cancers, viral diseases, and immune-deficiency disorders within the United States. The company, which was originally founded in 1966 and known as Hemispherx Biopharma, Inc., underwent a name change to AIM ImmunoTech Inc. in August 2019, marking a new phase in its operation. With its headquarters in Ocala, Florida, AIM ImmunoTech Inc. has established several strategic agreements with entities such as Amarex Clinical Research LLC, University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente, Jubilant HollisterStier, Sterling Pharma Solutions, Erasmus University Medical Center Rotterdam, Azenova, LLC, and Alcami Corporation. These collaborations underscore the company’s commitment to advancing its pipeline of innovative treatments.
Products and Services
- Ampligen
- Alferon N Injection
As AIM ImmunoTech's leading product candidate, Ampligen represents a significant advancement in the treatment of Chronic Fatigue Syndrome (CFS) with its unique composition of macromolecular ribonucleic acid molecules. Beyond CFS, the company is expanding its potential applications to a broader spectrum of diseases, including pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers. Additionally, it is being developed for conditions such as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions, showcasing the versatility of this innovative therapeutic.
This injectable formulation of natural alpha interferon offered by AIM ImmunoTech is approved for the treatment of human papillomavirus (HPV) infections and genital warts, a common sexually transmitted disease. Alferon N Injection highlights the company's commitment to addressing a range of infectious diseases with effective treatment options.
Contact Information
